Launched for DLBCL in 2020.Side effects include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia [171].Thrombocytopenia addressed by platelet transfusions and thrombopoietin receptor agonists.Granulocyte colony stimulating factors were effective at resolving neutropenia.The central nervous system mediated anorexia with weight loss and malaise limits the frequency of dosing to two or three times per week. The gene discussed is MPL; the disease is Decreased total neutrophil count.